Wanbury Limited

Wanbury Limited

Wanbury Limited's subsidiary Wanbury Skin Health Limited has launched its berrysoft baby product range across multiple states in India, marking a strategic entry into the Paediatric Dermatology segment.

Wanbury Limited

Wanbury Limited's subsidiary Wanbury Skin Health Limited has launched its berrysoft baby product range across multiple states in India, marking a strategic entry in the Paediatric Dermatology segment.

Wanbury Limited

Wanbury Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended September, 2026.

Wanbury Limited

Wanbury Limited has filed new Drug Master Files (DMFs) in South Africa, Philippines, and Singapore for Tramadol HCl API and Metformin HCl API, and added Key Starting Materials (KSM) vendors to ensure supply chain continuity for its CEP filed API, Paroxetine HCl.

Wanbury Limited

Wanbury Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Wanbury Limited

Wanbury Limited submitted the Exchange a copy of the Scrutinizer Report of the 38th Annual General Meeting held on September 24, 2026, along with the voting results. The company informed the Exchange regarding the voting results and enclosed the Scrutinizer Report submitted by Ms. Kala Agarwal, Practicing Company Secretary.

Wanbury Limited

Wanbury Limited has informed the Exchange about change in Management, specifically the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director beyond the age of 70 and the appointment and ratification of remuneration payable to M/s. ABK & Associates, Cost Accountant, for conducting cost audit for the Financial Year 2026-2027.

Wanbury Limited

Wanbury Limited has held its 38th Annual General Meeting (AGM) on September 24, 2026, where all resolutions were passed with the requisite majority. The meeting was conducted through video conferencing, and the voting results will be available on the company's website within 48 hours.

Wanbury Limited

Wanbury Limited has informed the Exchange about the 38th Annual General Meeting to be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM) on September 24, 2026.

Wanbury Limited

Wanbury Limited has announced the record date for its 38th Annual General Meeting (AGM) as September 18, 2026, and the meeting will be held on September 24, 2026.

Wanbury Limited

Wanbury Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2026.

Wanbury Limited

Wanbury Limited has informed the Exchange about Copy of Newspaper Publication regarding 38th Annual General Meeting to be held on Thursday, September 24, 2026 at 11:30 a.m. through Video Conferencing (VC)/Other Audio Visual Means (OAVM).

Wanbury Limited

Wanbury Limited has received approval from the European Directorate for the Quality of Medicines and Healthcare (EDQM) for its new product Rivaroxaban API, and also received DMF clearance for Paraxetine HCI and Metformin HCI from the USFDA.

Wanbury Limited

Wanbury Limited has announced its un-audited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 165.6 crore, a growth of 1.5% YoY. Gross profit stood at Rs. 86.9 crore, with a gross margin contraction to 52.5% due to an unprecedented sudden increase in input costs. EBITDA stood at Rs. 16.6 crore, with an EBITDA margin at 10.0%. PAT stood at Rs. 3.2 crore, with EPS of Rs. 0.93.

Wanbury Limited

Wanbury Limited has informed the Exchange regarding allotment of 27,530 securities pursuant to ESOP/ESPS at its meeting held on August 11, 2026, and also announced its un-audited financial results for the first quarter and three months ended June 30, 2026, along with the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director.

Wanbury Limited

Wanbury Limited has informed the Exchange about change in Management, with the Board of Directors approving the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for a term of five years, and the allotment of 27,530 Equity Shares to eligible employees upon exercise of vested options.

Wanbury Limited

Wanbury Limited has submitted its financial results for the period ended June 30, 2026, and approved the allotment of 27,530 equity shares to eligible employees under the Employee Stock Option Plan 2016. The company also re-appointed Mr. Mohan Kumar Rayana as a Whole-time Director for a term of five years.

Wanbury Limited

Wanbury Limited has informed the Exchange that it has received a 'No DMF deficiency letter' from the USFDA for multiple ANDAs, indicating full compliance with regulatory requirements.

Wanbury Limited

Wanbury Limited has informed the Exchange about General Updates, specifically the completion of a routine current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (USFDA) at the Company's facility at Tanuku, West Godavari District, Andhra Pradesh. The inspection resulted in six observations, and the Company will respond to these observations within the stipulated time.

Wanbury Limited

Wanbury Limited has informed the Exchange about the completion of a routine current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (USFDA) at its facility in Tanuku, West Godavari District, Andhra Pradesh. The inspection was conducted from July 13, 2026 to July 17, 2026, and the USFDA issued a Form 483 with six observations. The company will respond to these observations within the stipulated time.